type
diabet
mellitu
becom
crucial
threat
human
health
approxim
million
individu
worldwid
estim
number
exhibit
increas
three
decad
patient
might
suffer
pancreat
dysfunct
reduc
insulin
sensit
target
tissu
chronic
hyperglycemia
caus
macrovascular
microvascular
complic
remodel
heart
kidney
eye
nerv
oral
antidiabet
agent
includ
metformin
sulfonylurea
glucosidas
inhibitor
thiazolidinedion
meglitinid
inhibitor
dipeptidyl
peptidas
substanti
improv
prognosi
patient
howev
efficaci
western
medic
remain
defici
certain
patient
vastli
disproportion
burden
patient
low
middleincom
countri
henc
complementari
altern
therapi
tradit
chines
herbal
medic
requir
prolong
life
expect
improv
qualiti
life
patient
although
tradit
chines
herbal
medic
wide
use
year
east
asia
previou
studi
suggest
chines
herbal
medic
effect
treat
evid
base
random
control
trial
rct
still
feebl
tangminl
pill
mainli
contain
rhizoma
coptidi
rheum
officinal
baill
scutellaria
baicalensi
georgi
bupleurum
chinens
dc
might
reduc
blood
glucos
level
improv
pancreat
function
howev
studi
focus
effect
tangminl
pill
limit
due
insuffici
sampl
size
inconclus
result
studi
perform
pool
analysi
evalu
effect
tangminl
pill
blood
glucos
bodi
weight
function
patient
pharmaceut
composit
tangminl
pill
compris
extract
follow
ten
tradit
chines
herb
rhizoma
coptidi
huanglian
scutellaria
baicalensi
georgi
huangqin
radix
paeonia
alba
baishao
rheum
officinal
baill
dahuang
citru
aurantium
l
zhishi
pinellia
ternat
baixia
crataegu
pinnatifida
bung
shanzha
smoke
plum
fructu
mume
wumei
radix
trichosanthi
tianhuafen
bupleurum
chinens
dc
chaihu
option
compris
pharmaceut
accept
excipi
method
prepar
tangminl
pill
dose
ten
crude
herb
disclos
public
http
manufactur
capsul
specif
process
chines
herbal
medicin
tasli
pharmaceut
tianjin
china
describ
previous
quantit
control
limit
raw
herb
final
product
content
berberin
rhizoma
coptidi
shall
mgg
content
paeoniflorin
radix
paeonia
alba
shall
mgg
chemic
composit
tangminl
pill
analyz
use
highperform
liquid
chromatographymass
spectrometri
hplcm
method
studi
project
conform
ethic
rule
helsinki
declar
revis
edit
octob
approv
ethic
committe
shandong
univers
qilu
hospit
date
approv
juli
relev
rct
identifi
follow
data
sourc
medlin
china
vip
china
nation
knowledg
internet
china
wanfang
cochran
librari
literatur
search
term
tangminl
tangminl
tml
diabet
public
statu
languag
date
restrict
includ
studi
follow
criteria
compar
tangminl
treatment
vs
placebo
treatment
patient
ii
rct
followup
durat
iii
contain
avail
data
estim
pool
weight
mean
differ
wmd
correspond
confid
interv
ci
studi
exclud
follow
diagnosi
definit
ii
studi
nonrandom
andor
nondoubleblind
iii
differ
tradit
chines
medic
compar
two
group
iv
symptomat
chang
describ
without
object
laboratori
measur
v
methodolog
qualiti
poor
jadad
score
describ
previous
vi
two
articl
report
result
trial
articl
less
inform
exclud
extract
follow
inform
retriev
report
use
standard
protocol
author
name
public
date
studi
design
countri
origin
subject
number
subject
characterist
baselin
followup
durat
concomit
medic
end
point
literatur
search
data
extract
perform
blindli
two
author
jc
yl
accord
standard
approach
disagr
resolv
consensu
third
review
ph
revman
softwar
version
use
pool
analysi
heterogen
evalu
cochran
q
statist
inconsist
index
heterogen
consid
statist
signific
chisquar
p
pool
wmd
ci
analyz
differ
consid
statist
signific
twotail
p
moreov
sensit
analys
perform
evalu
individu
effect
explain
possibl
heterogen
addit
calcul
failsaf
number
nf
k
k
number
retriev
studi
assess
public
bia
valu
smaller
number
includ
trial
indic
obviou
public
bia
exist
first
perform
pool
analysi
evalu
effect
tangminl
pill
blood
glucos
level
blood
glucos
improv
evalu
reduct
hemoglobin
fast
plasma
glucos
fpg
postprandi
glucos
pg
level
baselin
four
studi
tabl
show
tangminl
pill
significantli
reduc
vs
p
fpg
vs
mm
p
pg
level
vs
mm
p
patient
compar
placebo
group
also
tangminl
pill
significantli
amelior
obes
express
reduct
waist
circumfer
wc
bodi
mass
index
bmi
patient
tabl
tangminl
significantli
reduc
wc
vs
cm
p
bmi
vs
baselin
comparison
placebo
treatment
patient
furthermor
show
tangminl
pill
significantli
improv
pancreat
function
express
homeostat
model
assess
homa
decreas
baselin
tabl
although
differ
reduc
homainsulin
resist
ir
tangminl
placebo
group
vs
p
tangminl
significantli
decreas
level
baselin
compar
placebo
vs
p
furthermor
safeti
tangminl
pill
also
confirm
without
seriou
advers
event
report
four
rct
heterogen
welladdress
term
howev
signific
heterogen
exist
term
fpg
bmi
wc
homair
alter
pool
wmd
signific
exclud
studi
largest
sampl
size
data
shown
thereaft
subgroup
analys
accord
fpg
bmi
wc
homair
conduct
tabl
heterogen
among
trial
partial
explain
variabl
dose
medic
subject
number
valu
fpg
pg
bmi
wc
homair
higher
number
studi
includ
correspond
analys
indic
neglig
public
bia
analys
pool
analys
indic
tangminl
pill
efficaci
decreas
glucos
level
bodi
weight
improv
function
drugrel
advers
event
placebo
treatment
patient
tradit
chines
medic
mainli
edibl
herb
wide
use
clinic
practic
china
year
ten
tradit
chines
herb
extract
includ
tangminl
pill
rhizoma
coptidi
scutellaria
baicalensi
georgi
radix
paeonia
alba
rheum
officinal
baill
citru
aurantium
l
pinellia
ternat
crataegu
pinnatifida
bung
smoke
plum
fructu
mume
radix
trichosanthi
bupleurum
chinens
dc
tabl
three
bioactiv
alkaloid
isol
rhizoma
coptidi
includ
berberin
coptisin
jatrorrhizin
berberin
numer
pharmacolog
effect
antidiabet
antiinflammatori
antihypercholesterolemia
cardioprotect
properti
berberin
display
benefici
action
treatment
insulinresist
hyperglycem
state
upregul
adipos
triglycerid
lipas
adipocyt
via
activ
adenosin
amp
activ
protein
kinas
ampk
signal
pathway
might
improv
glucos
metabol
via
inhibit
oxid
aldos
reductas
besid
berberin
might
exert
antiinflammatori
action
ampk
activ
nuclear
inhibit
pathway
inhibit
coptisin
anoth
bioactiv
compon
rhizoma
coptidi
exhibit
antioxid
antiosteosarcoma
antiinflamm
neuroprotect
anticanc
action
prevent
express
activ
akt
cjun
ntermin
kinas
jnk
nuclear
factor
erythroid
factor
nad
p
h
quinin
oxidoreductas
signal
pathway
inhibit
lipopolysaccharid
lp
tolllik
mediat
pathway
rheum
officinal
baill
root
rhizom
rheum
palmatum
l
antioxid
antiplatelet
aggreg
antiinflammatori
properti
underli
mechan
might
involv
reduct
mrna
express
acid
mammalian
chitinas
chitinas
protein
well
inhibit
progress
inflamm
bupleurum
chinens
dc
bioactiv
ingredi
saikosaponin
exhibit
immunomodulatori
antivir
hepatoprotect
anticanc
effect
induc
cell
cycl
arrest
cell
apoptosi
moreov
albiflorin
extract
radix
paeonia
alba
paeonia
lactiflora
exert
antidepress
antiallerg
effect
biosynthesi
allopregnanolon
inhibit
mast
cell
activ
main
activ
ingredi
scutellaria
baicalensi
georgi
baicalin
wogonin
exhibit
protect
diabet
complic
baicalin
reduc
renal
fibrosi
downregul
transform
growth
pathway
also
protect
effect
via
improv
islet
function
furthermor
wogonin
allevi
diabet
cardiomyopathi
diabetesrel
cognit
deficit
metabol
syndrom
wogonin
improv
peroxisom
proliferatoractiv
receptor
ppar
activ
adipocyt
type
diabet
mice
flavanon
naringenin
hesperetin
citru
aurantium
l
exhibit
antidepress
antioxid
antiatherogen
effect
pinellia
ternat
anticanc
proinflammatori
action
also
attenu
mucu
secret
airway
inflamm
rat
chronic
obstruct
pulmonari
diseas
crataegu
pinnatifida
bung
exert
antiinflammatori
effect
decreas
risk
cardiovascular
diseas
lower
blood
cholesterol
fructu
mume
exhibit
neuroprotect
effect
downregul
inflamm
inhibit
mapk
signal
radix
trichosanthi
play
anticanc
immunosuppress
role
combin
compon
tangminl
pill
might
exert
benefici
effect
patient
studi
safeti
tangminl
pill
also
confirm
without
seriou
advers
event
report
includ
rct
howev
product
tradit
chines
medicin
complic
necessari
test
effect
safeti
plant
extract
investig
easier
prepar
method
pill
formul
chronic
metabol
diseas
deterior
glycem
control
associ
progress
islet
dysfunct
chronic
inflamm
oxid
lipid
metabol
disturb
metabol
syndrom
character
presenc
abdomin
obes
ir
hyperglycemia
dyslipidemia
hypertens
tangminl
pill
significantli
improv
pancreat
function
reduc
bmi
wc
patient
analys
antihyperglycem
effect
tradit
chines
medic
might
attribut
part
protect
activ
ampk
signal
tangminl
found
increas
glucos
transport
level
ampk
activ
skelet
muscl
promot
insulin
secret
upregul
might
also
promot
prolifer
differenti
pancreat
therefor
postpon
exhaust
function
tangminl
show
improv
insulin
sensit
might
anoth
potenti
mechan
regul
glucos
metabol
disord
hypoglycemia
consid
major
barrier
proper
glycem
control
diabet
patient
analys
reveal
tangminl
reduc
blood
glucos
mildli
without
hypoglycem
event
report
tangminl
treatment
might
significantli
decreas
risk
hypoglycemia
result
better
qualiti
life
patient
besid
signific
heterogen
exist
analys
fpg
bmi
wc
homair
signific
dispar
sampl
size
among
four
rct
includ
pool
analys
fact
among
patient
includ
analys
one
studi
howev
exclud
studi
substanti
alter
found
pool
wmd
sever
limit
consid
analys
sampl
size
rel
small
number
includ
studi
limit
might
limit
power
estim
effect
tangminl
pill
intervent
followup
durat
studi
rel
short
therefor
highqual
studi
extend
intervent
larger
sampl
size
need
despit
limit
systemat
analysi
convinc
previou
singl
studi
inde
analysi
notabl
strength
strictli
adher
guidelin
rct
studi
includ
help
increas
robust
conclus
addit
paramet
use
assess
clinic
outcom
strict
increas
valid
studi
best
knowledg
first
pool
analysi
assess
effect
one
tradit
chines
medic
tangminl
pill
tangminl
pill
effect
safe
glycem
control
function
patient
could
use
treat
promis
complementari
approach
howev
rigor
design
trial
warrant
investig
impact
tangminl
pill
diabet
diabet
complic
